Search

Your search keyword '"Heikkinen, Terho"' showing total 571 results
Start Over Author "Heikkinen, Terho"
571 results on '"Heikkinen, Terho"'

1. The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus.

Author

Langedijk, Annefleur, Vrancken, Bram, Lebbink, Robert, Wilkins, Deidre, Kelly, Elizabeth, Baraldi, Eugenio, Mascareñas de Los Santos, Abiel, Danilenko, Daria, Choi, Eun, Palomino, María, Chi, Hsin, Keller, Christian, Cohen, Robert, Papenburg, Jesse, Pernica, Jeffrey, Greenough, Anne, Richmond, Peter, Martinón-Torres, Federico, Heikkinen, Terho, Stein, Renato, Hosoya, Mitsuaki, Nunes, Marta, Verwey, Charl, Evers, Anouk, Kragten-Tabatabaie, Leyla, Suchard, Marc, Kosakovsky Pond, Sergei, Poletto, Chiara, Colizza, Vittoria, Lemey, Philippe, and Bont, Louis

Subjects
Infant, Child, Humans, Child, Preschool, Respiratory Syncytial Virus Infections, Phylogeny, Respiratory Syncytial Virus, Human, Genomics, Respiratory Tract Infections
Abstract

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infection in young children and the second leading cause of infant death worldwide. While global circulation has been extensively studied for respiratory viruses such as seasonal influenza, and more recently also in great detail for SARS-CoV-2, a lack of global multi-annual sampling of complete RSV genomes limits our understanding of RSV molecular epidemiology. Here, we capitalise on the genomic surveillance by the INFORM-RSV study and apply phylodynamic approaches to uncover how selection and neutral epidemiological processes shape RSV diversity. Using complete viral genome sequences, we show similar patterns of site-specific diversifying selection among RSVA and RSVB and recover the imprint of non-neutral epidemic processes on their genealogies. Using a phylogeographic approach, we provide evidence for air travel governing the global patterns of RSVA and RSVB spread, which results in a considerable degree of phylogenetic mixing across countries. Our findings highlight the potential of systematic global RSV genomic surveillance for transforming our understanding of global RSV spread.

Published
2024

2. The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children

Author

Kristensen, Maartje, de Steenhuijsen Piters, Wouter A.A., Wildenbeest, Joanne, van Houten, Marlies A., Zuurbier, Roy P., Hasrat, Raiza, Arp, Kayleigh, Chu, Mei Ling J.N., Billard, Marie, Heikkinen, Terho, Cunningham, Steve, Snape, Matthew, Drysdale, Simon B., Thwaites, Ryan S., Martinon-Torres, Federico, Pollard, Andrew J., Openshaw, Peter J.M., Aerssens, Jeroen, Binkowska, Justyna, Bont, Louis, and Bogaert, Debby

Published
2024
Full Text
View/download PDF

3. Estimation of respiratory syncytial virus-associated hospital admissions in five European countries: a modelling study

Author

Nair, Harish, Nohynek, Hanna, Teirlinck, Anne, Bont, Louis, Openshaw, Peter, Pollard, Andrew, Kumar, Veena, Begier, Elizabeth, Janimak, Jim, Hendrix, Jenny, Kramer, Rolf, Sánchez, Alejandro Orrico, Molero, Eva, Johannesen, Caroline Klint, Gideonse, David, Osei-Yeboah, Richard, Lehtonen, Toni, Jollivet, Ombeline, Cohen, Rachel A., Urchueguía-Fornes, Arantxa, Herrero-Silvestre, María, López-Lacort, Mónica, Fischer, Thea K., Heikkinen, Terho, Campbell, Harry, and van Boven, Michiel

Published
2025
Full Text
View/download PDF

4. Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis

Author

Mrčela, Dina, Milić, Petra, Veljačić Visković, Daniela, Torres-Fernandez, David, Urchueguía, Arantxa, Díez-Domingo, Javier, Orrico-Sánchez, Alejandro, Walaza, Sibongile, Gottberg, Anne von, Reubenson, Gary, Dawood, Halima, Mekgoe, Omphile, Plessis, Mignon du, Baute, Neydis, Naby, Fathima, Keck, James W, Dobson, Jennifer, Hartman, Rachel, Sandoval, Marqia, Bressler, Sara S, Bruden, Dana, Karseladze, Irakli, Shchomak, Zakhar, Barreto, Rosário, Murunga, Nickson, Mutunga, Martin, Casalegno, Jean-Sebastien, Horvat, Come, Cong, Bingbing, Koç, Uğurcan, Bandeira, Teresa, Bassat, Quique, Bont, Louis, Chakhunashvili, Giorgi, Cohen, Cheryl, Desnoyers, Christine, Hammitt, Laura L, Heikkinen, Terho, Huang, Q Sue, Markić, Joško, Mira-Iglesias, Ainara, Moyes, Jocelyn, Nokes, D James, Ploin, Dominique, Seo, Euri, Singleton, Rosalyn, Wolter, Nicole, Fu Yung, Chee, Zar, Heather J, Feikin, Daniel R, Sparrow, Erin G, Nair, Harish, and Li, You

Published
2024
Full Text
View/download PDF

5. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data

Author

Arruda, Eurico, Baillie, Vicky L, Chong, Debora, Crow, Rowena, Filho, Nelson Rosário, Laubscher, Marius, Madhi, Shabir A, Mrcela, Dina, Ramilo, Octavio, Roje, Damir, Stein, Renato Tetelbom, Yung, Chee Fu, Wang, Xin, Li, You, Shi, Ting, Bont, Louis J, Chu, Helen Y, Zar, Heather J, Wahi-Singh, Bhanu, Ma, Yiming, Cong, Bingbing, Sharland, Emma, Riley, Richard D, Deng, Jikui, Figueras-Aloy, Josep, Heikkinen, Terho, Jones, Marcus H, Liese, Johannes G, Markić, Joško, Mejias, Asuncion, Nunes, Marta C, Resch, Bernhard, Satav, Ashish, Yeo, Kee Thai, Simões, Eric A F, and Nair, Harish

Published
2024
Full Text
View/download PDF

6. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data

Author

Clement, Pascale, Gupta, Atul, Hashimoto, Koichi, Komissarova, Kseniya, Laubscher, Matt, Lumertz, Magali, Priante, Elena, Rivero-Calle, Irene, Wadia, Ushma, Yun, Ki Wook, Wilkins, Deidre, Langedijk, Annefleur C, Lebbink, Robert Jan, Morehouse, Christopher, Abram, Michael E, Ahani, Bahar, Aksyuk, Anastasia A, Baraldi, Eugenio, Brady, Tyler, Chen, Albert Tian, Chi, Hsin, Choi, Eun Hwa, Cohen, Robert, Danilenko, Daria M, Gopalakrishnan, Vancheswaran, Greenough, Anne, Heikkinen, Terho, Hosoya, Mitsuaki, Keller, Christian, Kelly, Elizabeth J, Kragten-Tabatabaie, Leyla, Martinón-Torres, Federico, de Los Santos, Abiel Homero Mascareñas, Nunes, Marta C, Palomino, María Angélica, Papenburg, Jesse, Pernica, Jeffrey M, Richmond, Peter, Stein, Renato T, Tuffy, Kevin M, Verwey, Charl, Esser, Mark T, Tabor, David E, and Bont, Louis J

Published
2023
Full Text
View/download PDF

7. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape

Author

Mazur, Natalie I, Terstappen, Jonne, Baral, Ranju, Bardají, Azucena, Beutels, Philippe, Buchholz, Ursula J, Cohen, Cheryl, Crowe, James E, Jr, Cutland, Clare L, Eckert, Linda, Feikin, Daniel, Fitzpatrick, Tiffany, Fong, Youyi, Graham, Barney S, Heikkinen, Terho, Higgins, Deborah, Hirve, Siddhivinayak, Klugman, Keith P, Kragten-Tabatabaie, Leyla, Lemey, Philippe, Libster, Romina, Löwensteyn, Yvette, Mejias, Asuncion, Munoz, Flor M, Munywoki, Patrick K, Mwananyanda, Lawrence, Nair, Harish, Nunes, Marta C, Ramilo, Octavio, Richmond, Peter, Ruckwardt, Tracy J, Sande, Charles, Srikantiah, Padmini, Thacker, Naveen, Waldstein, Kody A, Weinberger, Dan, Wildenbeest, Joanne, Wiseman, Dexter, Zar, Heather J, Zambon, Maria, and Bont, Louis

Published
2023
Full Text
View/download PDF

8. Year-to-year variation in attack rates could result in underpowered respiratory syncytial virus vaccine efficacy trials

Author

Marie-Noelle Billard, Rengerink, Katrien Oude, Bont, Louis, Wildenbeest, Joanne, Nair, Harish, Campbell, Harry, Beutels, Philippe, Openshaw, Peter, Pollard, Andrew, Martinon-Torres, Federico, Heikkinen, Terho, Meijer, Adam, Fischer, Thea Kølsen, van den Berge, Maarten, Giaquinto, Carlo, Aerssens, Jeroen, Abram, Michael, Swanson, Kena, Demont, Clarisse, Gallichan, Scott, Kumar, Veena, Stoszek, Sonia, Molero, Eva, Billard, Marie-Noëlle, Bont, Louis J., McCracken, John P., and Oude Rengerink, Katrien

Published
2022
Full Text
View/download PDF

9. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis

Author

Abram, Michael, Aerssens, Jeroen, Alafaci, Annette, Balmaseda, Angel, Bandeira, Teresa, Barr, Ian, Batinović, Ena, Beutels, Philippe, Bhiman, Jinal, Blyth, Christopher C, Bont, Louis, Bressler, Sara S, Cohen, Cheryl, Cohen, Rachel, Costa, Anna-Maria, Crow, Rowena, Daley, Andrew, Dang, Duc-Anh, Demont, Clarisse, Desnoyers, Christine, Díez-Domingo, Javier, Divarathna, Maduja, du Plessis, Mignon, Edgoose, Madeleine, Ferolla, Fausto Martín, Fischer, Thea K, Gebremedhin, Amanuel, Giaquinto, Carlo, Gillet, Yves, Hernandez, Roger, Horvat, Come, Javouhey, Etienne, Karseladze, Irakli, Kubale, John, Kumar, Rakesh, Lina, Bruno, Lucion, Florencia, MacGinty, Rae, Martinon-Torres, Federico, McMinn, Alissa, Meijer, Adam, Milić, Petra, Morel, Adrian, Mulholland, Kim, Mungun, Tuya, Murunga, Nickson, Newbern, Claire, Nicol, Mark P, Odoom, John Kofi, Openshaw, Peter, Ploin, Dominique, Polack, Fernando P, Pollard, Andrew J, Prasad, Namrata, Puig-Barberà, Joan, Reiche, Janine, Reyes, Noelia, Rizkalla, Bishoy, Satao, Shilpa, Shi, Ting, Sistla, Sujatha, Snape, Matthew, Song, Yanran, Soto, Giselle, Tavakoli, Forough, Toizumi, Michiko, Tsedenbal, Naranzul, van den Berge, Maarten, Vernhes, Charlotte, von Mollendorf, Claire, Walaza, Sibongile, Walker, Gregory, Li, You, Wang, Xin, Blau, Dianna M, Caballero, Mauricio T, Feikin, Daniel R, Gill, Christopher J, Madhi, Shabir A, Omer, Saad B, Simões, Eric A F, Campbell, Harry, Pariente, Ana Bermejo, Bardach, Darmaa, Bassat, Quique, Casalegno, Jean-Sebastien, Chakhunashvili, Giorgi, Crawford, Nigel, Danilenko, Daria, Do, Lien Anh Ha, Echavarria, Marcela, Gentile, Angela, Gordon, Aubree, Heikkinen, Terho, Huang, Q Sue, Jullien, Sophie, Krishnan, Anand, Lopez, Eduardo Luis, Markić, Joško, Mira-Iglesias, Ainara, Moore, Hannah C, Moyes, Jocelyn, Mwananyanda, Lawrence, Nokes, D James, Noordeen, Faseeha, Obodai, Evangeline, Palani, Nandhini, Romero, Candice, Salimi, Vahid, Satav, Ashish, Seo, Euri, Shchomak, Zakhar, Singleton, Rosalyn, Stolyarov, Kirill, Stoszek, Sonia K, von Gottberg, Anne, Wurzel, Danielle, Yoshida, Lay-Myint, Yung, Chee Fu, Zar, Heather J, and Nair, Harish

Published
2022
Full Text
View/download PDF

12. Inconsistent Increase in Age at Respiratory Syncytial Virus Hospitalization of Children Aged <2 Years During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: A Retrospective Multicenter Study in 4 European Countries.

Author

Harding, Eline R, Wildenbeest, Joanne G, Heikkinen, Terho, Dacosta-Urbieta, Ana, Martinón-Torres, Federico, Cunningham, Steve, Templeton, Kate, Bont, Louis J, Billard, Marie-Noëlle, and investigators, PROMISE

Subjects
SARS-CoV-2, RESPIRATORY syncytial virus, PEDIATRIC intensive care, COVID-19 pandemic, INTENSIVE care units
Abstract

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic disrupted respiratory syncytial virus (RSV) seasonality. To optimize the use and evaluation of RSV infant immunization strategies, monitoring changes in RSV epidemiology is essential. Methods Hospitalizations for acute respiratory infections (ARIs) and RSV-coded ARI in children <2 years were extracted in 4 European hospitals, according to predefined case definitions (International Classification of Diseases, Tenth Revision codes). Prepandemic RSV seasons (2017–2018 to 2019–2020) were compared to 2021–2022 and 2022–2023. Results In 2021–2022 and 2022–2023, the peak number of RSV hospitalizations was higher than prepandemic peaks after short periods of RSV circulation, and lower than prepandemic peaks after long periods of RSV circulation. A greater proportion of RSV hospitalizations occurred in children 1 to <2 years in 2021–2022 in the Netherlands (18% vs 9%, P =.04). No increase in age was observed elsewhere. High-risk children represented a greater proportion of RSV hospitalizations during the pandemic. The proportion of pediatric intensive care unit admissions did not increase. Conclusions A decrease in population immunity has been linked to older age at RSV hospitalization. We did not observe an increase in age in 3 of the 4 participating countries. Broad age categories may have prevented detecting an age shift. Monitoring RSV epidemiology is essential as Europe implements RSV immunization. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study

Author

Nair, Harish, Campbell, Harry, Wang, Xin, Li, You, Chung, Alexandria, Rahi, Manveer, Abbas, Qalab, Ali, Asad, Bhutta, Zulfiqar A, Saeed, Bushra, Soofi, Sajid B, Yousafzai, Mohammad Tahir, Zaidi, Anita K, Amu, Alberta, Awini, Elizabeth, Azziz-Baumgartner, Eduardo, Baggett, Henry C, Chaves, Sandra S, Shang, Nong, Schrag, Stephanie J, Widdowson, Marc-Alain, Tempia, Stefano, Bassat, Quique, Lanaspa, Miguel, Acácio, Sozinho, Brooks, W Abdullah, Driscoll, Amanda, Knoll, Maria Deloria, O'Brien, Katherine L, Prosperi, Christine, Baqui, Abdullah H, Mullany, Luke, Byass, Peter, Cohen, Cheryl, von Gottberg, Anne, Hellferscee, Orienka, Treurnicht, Florette K, Walaza, Sibongile, Goswami, Doli, Rahman, Mustafizur, Connor, Nicholas E, El Arifeen, Shams, Echavarria, Marcela, Marcone, Débora N, Reyes, Noelia, Gutierrez, Andrea, Rodriguez, Ivan, Lopez, Olga, Ortiz, David, Gonzalez, Nathaly, Gentile, Angela, del Valle Juarez, Maria, Gordon, Aubree, Cutland, Clare, Groome, Michelle, Madhi, Shabir A, Nunes, Marta C, Nzenze, Susan, Heikkinen, Terho, Hirve, Siddhivinayak, Juvekar, Sanjay, Halasa, Natasha, Jara, Jorge H, Bernart, Chris, Katz, Mark A, Gofer, Ilan, Avni, Yonat Shemer, Khuri-Bulos, Najwa, Faori, Samir, Shehabi, Asem, Krishnan, Anand, Kumar, Rakesh, Amarchand, Ritvik, Contreras, Carmen L, de Leon, Oscar, Lopez, Maria R, McCracken, John P, Maldonado, Herberth, Samayoa, Antonio P, Gomez, Ana B, Lucero, Marilla G, Nillos, Leilani T, Lupisan, Socorro P, Nohynek, Hanna, Mira-Iglesias, Ainara, Puig-Barberà, Joan, Díez-Domingo, Javier, Gessner, Bradford D, Njanpop-Lafourcade, Berthe-Marie, Moïsi, Jennifer C, Tall, Haoua, Munywoki, Patrick K, Ngama, Mwanjuma, Nokes, D James, Omer, Saad B, Clark, Dayna R, Ourohiré, Millogo, Ali, Sié, Pascal, Zabré, Cheik, Bagagnan H, Caballero, Mauricio T, Libster, Romina, Polack, Fernando P, Rasmussen, Zeba A, Thomas, Elizabeth D, Baker, Julia M, Rath, Barbara A, Obermeier, Patrick E, Hassanuzzaman, MD., Islam, Maksuda, Islam, Mohammad S, Saha, Samir K, Panigrahi, Pinaki, Bose, Anuradha, Isaac, Rita, Murdoch, David, Nanda, Pritish, Qazi, Shamim A, Hessong, Danielle, Simőes, Eric AF, Sotomayor, Viviana, Thamthitiwat, Somsak, Chittaganpitch, Malinee, Dawood, Halima, Kyobutungi, Catherine, Wamukoya, Marylene, Ziraba, Abdhalah K, Yoshida, Lay-Myint, Yoshihara, Keisuke, Dand, Duc-Anh, Le, Minh-Nhat, Nicol, Mark P, Zar, Heather J, Broor, Shobha, Chadha, Mandeep, Madrid, Lola, Gresh, Lionel, Balmaseda, Angel, Kuan, Guillermina, Wairagkar, Niteen, Tapia, Milagritos D, Knobler, Stacey L, Barahona, Alfredo, Ferguson, Ericka, Schweiger, Brunhilde, Abdullah Brooks, W, Fasce, Rodrigo A, and Simões, Eric AF

Published
2020
Full Text
View/download PDF

15. Effectiveness of Vaccines and Monoclonal Antibodies Against Respiratory Syncytial Virus: Generic Protocol for Register-Based Cohort Study

Author

CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Child Health, Infection & Immunity, Poukka, Eero, Roekel, Caren van, Turunen, Topi, Baum, Ulrike, Kramer, Rolf, Begier, Elizabeth, Presser, Lance D., Teirlinck, Anne C., Heikkinen, Terho, Knol, Mirjam, Nohynek, Hanna, Bont, Louis, PROMISE investigators, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Child Health, Infection & Immunity, Poukka, Eero, Roekel, Caren van, Turunen, Topi, Baum, Ulrike, Kramer, Rolf, Begier, Elizabeth, Presser, Lance D., Teirlinck, Anne C., Heikkinen, Terho, Knol, Mirjam, Nohynek, Hanna, Bont, Louis, and PROMISE investigators

Published
2024

16. Effectiveness of Immunization Products Against Medically Attended Respiratory Syncytial Virus Infection: Generic Protocol for a Test-Negative Case-Control Study

Author

CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Child Health, Infection & Immunity, Roekel, Caren Van, Poukka, Eero, Turunen, Topi, Nohynek, Hanna, Presser, Lance, Meijer, Adam, Heikkinen, Terho, Kramer, Rolf, Begier, Elizabeth, Teirlinck, Anne C., Knol, Mirjam, Bont, Louis, PROMISE investigators, CTI Bont, Infectieziekten onderzoek1 (Bont), Zorg en O&O, Child Health, Infection & Immunity, Roekel, Caren Van, Poukka, Eero, Turunen, Topi, Nohynek, Hanna, Presser, Lance, Meijer, Adam, Heikkinen, Terho, Kramer, Rolf, Begier, Elizabeth, Teirlinck, Anne C., Knol, Mirjam, Bont, Louis, and PROMISE investigators

Published
2024

17. The genomic evolutionary dynamics and global circulation patterns of respiratory syncytial virus

Author

Langedijk, Annefleur A.C., Vrancken, Bram, Lebbink, Robert Jan, Wilkins, Deidre, Kelly, Elizabeth E.J., Baraldi, Eugenio, Mascareñas de Los Santos, Abiel Homero, Danilenko, Daria D.M., Choi, Eun Hwa, Palomino, María Angélica, Chi, Hsin, Keller, Christian, Cohen, Robert, Papenburg, Jesse, Pernica, Jeffrey, Greenough, Anne, Richmond, Peter, Martinón-Torres, Federico, Heikkinen, Terho, Stein, Renato Tetelbom, Hosoya, Mitsuaki, Nunes, Marta M.C., Verwey, Charl, Evers, Anouk, Kragten-Tabatabaie, Leyla, Suchard, Marc M.A., Kosakovsky Pond, Sergei S.L., Poletto, Chiara, Colizza, Vittoria, Lemey, Philippe, Bont, Louis, Langedijk, Annefleur A.C., Vrancken, Bram, Lebbink, Robert Jan, Wilkins, Deidre, Kelly, Elizabeth E.J., Baraldi, Eugenio, Mascareñas de Los Santos, Abiel Homero, Danilenko, Daria D.M., Choi, Eun Hwa, Palomino, María Angélica, Chi, Hsin, Keller, Christian, Cohen, Robert, Papenburg, Jesse, Pernica, Jeffrey, Greenough, Anne, Richmond, Peter, Martinón-Torres, Federico, Heikkinen, Terho, Stein, Renato Tetelbom, Hosoya, Mitsuaki, Nunes, Marta M.C., Verwey, Charl, Evers, Anouk, Kragten-Tabatabaie, Leyla, Suchard, Marc M.A., Kosakovsky Pond, Sergei S.L., Poletto, Chiara, Colizza, Vittoria, Lemey, Philippe, and Bont, Louis

Abstract

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infection in young children and the second leading cause of infant death worldwide. While global circulation has been extensively studied for respiratory viruses such as seasonal influenza, and more recently also in great detail for SARS-CoV-2, a lack of global multi-annual sampling of complete RSV genomes limits our understanding of RSV molecular epidemiology. Here, we capitalise on the genomic surveillance by the INFORM-RSV study and apply phylodynamic approaches to uncover how selection and neutral epidemiological processes shape RSV diversity. Using complete viral genome sequences, we show similar patterns of site-specific diversifying selection among RSVA and RSVB and recover the imprint of non-neutral epidemic processes on their genealogies. Using a phylogeographic approach, we provide evidence for air travel governing the global patterns of RSVA and RSVB spread, which results in a considerable degree of phylogenetic mixing across countries. Our findings highlight the potential of systematic global RSV genomic surveillance for transforming our understanding of global RSV spread., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2024

18. Respiratory Syncytial Virus–Associated Hospitalization in Adults With Comorbidities in 2 European Countries:A Modeling Study

Author

Osei-Yeboah, Richard, Johannesen, Caroline Klint, Egeskov-Cavling, Amanda Marie, Chen, Junru, Lehtonen, Toni, Fornes, Arantxa Urchueguía, Paget, John, Fischer, Thea K., Wang, Xin, Nair, Harish, Campbell, Harry, Nohynek, Hanna, Teirlinck, Anne, van Boven, Michiel, Heikkinen, Terho, Bont, Louis, Openshaw, Peter, Beutels, Phillipe, Pollard, Andrew, Kumar, Veena, Sánchez, Alexandro Orrico, Gideonse, David, Htar, Tin Tin, Vernhes, Charlotte, Santos, Gael Dos, Cohen, Rachel, Aerssens, Jeroen, Kramer, Rolf, Jollivet, Ombeline, Manchin, Nuria, Osei-Yeboah, Richard, Johannesen, Caroline Klint, Egeskov-Cavling, Amanda Marie, Chen, Junru, Lehtonen, Toni, Fornes, Arantxa Urchueguía, Paget, John, Fischer, Thea K., Wang, Xin, Nair, Harish, Campbell, Harry, Nohynek, Hanna, Teirlinck, Anne, van Boven, Michiel, Heikkinen, Terho, Bont, Louis, Openshaw, Peter, Beutels, Phillipe, Pollard, Andrew, Kumar, Veena, Sánchez, Alexandro Orrico, Gideonse, David, Htar, Tin Tin, Vernhes, Charlotte, Santos, Gael Dos, Cohen, Rachel, Aerssens, Jeroen, Kramer, Rolf, Jollivet, Ombeline, and Manchin, Nuria

Abstract

Background Individuals with comorbidities are at increased risk of severe respiratory syncytial virus (RSV) infection. We estimated RSV-associated respiratory hospitalization among adults aged ≥45 years with comorbidities in Denmark and Scotland. Methods By analyzing national hospital and virologic data, we estimated annual RSV-associated hospitalizations by 7 selected comorbidities and ages between 2010 and 2018. We estimated rate ratios of RSV-associated hospitalization for adults with comorbidity than the overall population. Results In Denmark, annual RSV–associated hospitalization rates per 1000 adults ranged from 3.1 for asthma to 19.4 for chronic kidney disease (CKD). In Scotland, rates ranged from 2.4 for chronic liver disease to 9.0 for chronic obstructive pulmonary disease (COPD). In both countries, we found a 2- to 4-fold increased risk of RSV hospitalization for adults with COPD, ischemic heart disease, stroke, and diabetes; a 1.5- to 3-fold increased risk for asthma; and a 3- to 7-fold increased risk for CKD. RSV hospitalization rates among adults aged 45 to 64 years with COPD, asthma, ischemic heart disease, or CKD were higher than the overall population. Conclusions This study provides important evidence for identifying risk groups and assisting health authorities in RSV vaccination policy making., Background. Individuals with comorbidities are at increased risk of severe respiratory syncytial virus (RSV) infection. We estimated RSV-associated respiratory hospitalization among adults aged ≥45 years with comorbidities in Denmark and Scotland. Methods. By analyzing national hospital and virologic data, we estimated annual RSV-associated hospitalizations by 7 selected comorbidities and ages between 2010 and 2018. We estimated rate ratios of RSV-associated hospitalization for adults with comorbidity than the overall population. Results. In Denmark, annual RSV–associated hospitalization rates per 1000 adults ranged from 3.1 for asthma to 19.4 for chronic kidney disease (CKD). In Scotland, rates ranged from 2.4 for chronic liver disease to 9.0 for chronic obstructive pulmonary disease (COPD). In both countries, we found a 2- to 4-fold increased risk of RSV hospitalization for adults with COPD, ischemic heart disease, stroke, and diabetes; a 1.5- to 3-fold increased risk for asthma; and a 3- to 7-fold increased risk for CKD. RSV hospitalization rates among adults aged 45 to 64 years with COPD, asthma, ischemic heart disease, or CKD were higher than the overall population. Conclusions. This study provides important evidence for identifying risk groups and assisting health authorities in RSV vaccination policy making.

Published
2024

19. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data

Author

Wang, Xin, primary, Li, You, additional, Shi, Ting, additional, Bont, Louis J, additional, Chu, Helen Y, additional, Zar, Heather J, additional, Wahi-Singh, Bhanu, additional, Ma, Yiming, additional, Cong, Bingbing, additional, Sharland, Emma, additional, Riley, Richard D, additional, Deng, Jikui, additional, Figueras-Aloy, Josep, additional, Heikkinen, Terho, additional, Jones, Marcus H, additional, Liese, Johannes G, additional, Markić, Joško, additional, Mejias, Asuncion, additional, Nunes, Marta C, additional, Resch, Bernhard, additional, Satav, Ashish, additional, Yeo, Kee Thai, additional, Simões, Eric A F, additional, Nair, Harish, additional, Arruda, Eurico, additional, Baillie, Vicky L, additional, Chong, Debora, additional, Crow, Rowena, additional, Filho, Nelson Rosário, additional, Laubscher, Marius, additional, Madhi, Shabir A, additional, Mrcela, Dina, additional, Ramilo, Octavio, additional, Roje, Damir, additional, Stein, Renato Tetelbom, additional, and Yung, Chee Fu, additional

Published
2024
Full Text
View/download PDF

21. Respiratory Syncytial Virus Seasonality : A Global Overview

Author

Obando-Pacheco, Pablo, Justicia-Grande, Antonio José, Rivero-Calle, Irene, Rodríguez-Tenreiro, Carmen, Sly, Peter, Ramilo, Octavio, Mejías, Asunción, Baraldi, Eugenio, Papadopoulos, Nikolaos G., Nair, Harish, Nunes, Marta C., Kragten-Tabatabaie, Leyla, Heikkinen, Terho, Greenough, Anne, Stein, Renato T., Manzoni, Paolo, Bont, Louis, and Martinón-Torres, Federico

Published
2018

22. Global molecular diversity of RSV – the “INFORM RSV” study

Author

Langedijk, Annefleur C., Lebbink, Robert Jan, Naaktgeboren, Christiana, Evers, Anouk, Viveen, Marco C., Greenough, Anne, Heikkinen, Terho, Stein, Renato T., Richmond, Peter, Martinón-Torres, Federico, Nunes, Marta, Hosoya, Mitsuaki, Keller, Christian, Bauck, Monika, Cohen, Robert, Papenburg, Jesse, Pernica, Jeffrey, Hennus, Marije P., Jin, Hong, Tabor, David E., Tovchigrechko, Andrev, Ruzin, Alexey, Abram, Michael E., Wilkins, Deidre, Wildenbeest, Joanne G., Kragten-Tabatabaie, Leyla, Coenjaerts, Frank E. J., Esser, Mark T., and Bont, Louis J.

Published
2020
Full Text
View/download PDF

23. Substantial Burden of Nonmedically Attended RSV Infection in Healthy-Term Infants: An International Prospective Birth Cohort Study.

Author

Hak, Sarah F, Venekamp, Roderick P, Billard, Marie-Noëlle, Houten, Marlies A van, Pollard, Andrew J, Heikkinen, Terho, Cunningham, Steve, Millar, Margaret, Martinón-Torres, Federico, Dacosta-Urbieta, Ana, Bont, Louis J, Wildenbeest, Joanne G, and Investigators, PROMISE

Subjects
RESPIRATORY syncytial virus infections, COHORT analysis, RESPIRATORY syncytial virus, INFANTS, CLINICAL trial registries
Abstract

Background During the first year of life, 1 in 4 infants develops a symptomatic respiratory syncytial virus (RSV) infection, yet only half seek medical attention. The current focus on medically attended RSV therefore underrepresents the true societal burden of RSV. We assessed the burden of nonmedically attended RSV infections and compared with medically attended RSV. Methods We performed active RSV surveillance until the age of 1 year in a cohort (n = 993) nested within the Respiratory Syncytial Virus Consortium in EUrope (RESCEU) prospective birth cohort study enrolling healthy term-born infants in 5 European countries. Symptoms, medication use, wheezing, and impact on family life were analyzed. Results For 97 of 120 (80.1%) nonmedically attended RSV episodes, sufficient data were available for analysis. In 50.5% (49/97), symptoms lasted ≥15 days. Parents reported impairment in usual daily activities in 59.8% (58/97) of episodes; worries, 75.3% (73/97); anxiety, 34.0% (33/97); and work absenteeism, 10.8% (10/93). Compared with medically attended RSV (n = 102, 9 hospital admissions), Respiratory Syncytial Virus NETwork (ReSViNET) severity scores were lower (3.5 vs 4.6, P <.001), whereas duration of respiratory symptoms and was comparable. Conclusions Even when medical attendance is not required, RSV infection poses a substantial burden to infants, families, and society. These findings are important for policy makers when considering the implementation of RSV immunization. Clinical Trials Registration. ClinicalTrials.gov (NCT03627572). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Effectiveness of Vaccines and Monoclonal Antibodies Against Respiratory Syncytial Virus: Generic Protocol for Register-Based Cohort Study.

Author

Poukka, Eero, Roekel, Caren van, Turunen, Topi, Baum, Ulrike, Kramer, Rolf, Begier, Elizabeth, Presser, Lance, Teirlinck, Anne, Heikkinen, Terho, Knol, Mirjam, Nohynek, Hanna, and Investigators, PROMISE

Subjects
RESPIRATORY syncytial virus, MONOCLONAL antibodies, VACCINE effectiveness, COHORT analysis, RESEARCH personnel
Abstract

Several immunization products are currently being developed against respiratory syncytial virus (RSV) for children, pregnant females, and older adults, and some products have already received authorization. Therefore, studies to monitor the effectiveness of these products are needed in the following years. To assist researchers to conduct postmarketing studies, we developed a generic protocol for register-based cohort studies to evaluate immunization product effectiveness against RSV-specific and nonspecific outcomes. To conduct a study on the basis of this generic protocol, the researchers can use any relevant databases or healthcare registers that are available at the study site. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Effectiveness of Immunization Products Against Medically Attended Respiratory Syncytial Virus Infection: Generic Protocol for a Test-Negative Case-Control Study.

Author

Roekel, Caren van, Poukka, Eero, Turunen, Topi, Nohynek, Hanna, Presser, Lance, Meijer, Adam, Heikkinen, Terho, Kramer, Rolf, Begier, Elizabeth, Teirlinck, Anne C, Knol, Mirjam J, and Investigators, PROMISE

Subjects
RESPIRATORY syncytial virus infections, HUMAN metapneumovirus infection, CASE-control method, RESPIRATORY infections, IMMUNIZATION, RESPIRATORY syncytial virus
Abstract

Monitoring the real-life effectiveness of respiratory syncytial virus (RSV) products is of major public health importance. This generic protocol for a test-negative design study aims to address currently envisioned approaches for RSV prevention (monoclonal antibodies and vaccines) to study effectiveness of these products among target groups: children, older adults, and pregnant women. The generic protocol approach was chosen to allow for flexibility in adapting the protocol to a specific setting. This protocol includes severe acute respiratory infection (SARI) and acute respiratory infection (ARI), both due to RSV, as end points. These end points can be applied to studies in hospitals, primarily targeting patients with more severe disease, but also to studies in general practitioner clinics targeting ARI. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Time-varying association between severe respiratory syncytial virus infections and subsequent severe asthma and wheeze and influences of age at the infection

Author

Wang, Xin, Li, You, Nair, Harish, Campbell, Harry, Reeves, Rachel M, van Wijhe, Maarten, Kølsen Fischer, Thea, Simonsen, Lone, Trebbien, Ramona, Tong, Sabine, Bangert, Mathieu, Demont, Clarisse, Lehtonen, Toni, University Hospital, Turku, Heikkinen, Terho, Teirlinck, Anne, van Boven, Michiel, van der Hoek, Wim, van der Maas, Nicoline, Meijer, Adam, Vazquez Fernandez, Liliana, Bøas, Håkon, Bekkevold, Terese, Flem, Elmira, Stona, Luca, Speltra, Irene, Giaquinto, Carlo, Cheret, Arnaud, Leach, Amanda, Stoszek, Sonia, Beutels, Philippe, Bont, Louis, Pollard, Andrew, Openshaw, Peter, Abram, Michael, Swanson, Kena, Rosen, Brian, Molero, Eva, and Investigators, RESCEU

Subjects
medicine.medical_specialty, Respiratory Syncytial Virus Infections, Virus, Risk Factors, Wheeze, Internal medicine, medicine, Humans, Immunology and Allergy, Respiratory system, Child, Respiratory Sounds, Retrospective Studies, Asthma, business.industry, Hazard ratio, Infant, medicine.disease, Confidence interval, Infectious Diseases, medicine.anatomical_structure, Child, Preschool, Cohort, medicine.symptom, business, Respiratory tract
Abstract

Background Early-life severe respiratory syncytial virus (RSV) infection has been associated with subsequent risk of asthma and recurrent wheeze. However, changes in the association over time and the interaction effect of the age at first RSV infection are less well understood. We aimed to assess the time-varying association between RSV and subsequent asthma and wheeze admission and explore how the association was affected by the age at RSV infection. Methods We retrospectively followed up a cohort of 23 365 children for a median of 6.9 years using Scottish health databases. Children who were born between 2001 and 2013 and had RSV-associated respiratory tract infection (RTI) admissions under 2 years were in the exposed group; those with unintentional accident admissions under 2 years comprised the control group. The Cox proportional-hazards model was used to report adjusted hazard ratios (HRs) of RSV admissions on subsequent asthma and wheeze admissions. We did subgroup analyses by follow-up years. We also explored how this association was affected by the age at first RSV admission. Results The association was strongest in the first 2 years of follow-up and decreased over time. The association persisted for 6 years in children whose first RSV-RTI admission occurred at 6–23 months of age, with an adjusted HR of 3.9 (95% confidence interval [CI], 3.1–4.9) for the first 2 years, 2.3 (95% CI, 1.6–3.2) for 2 to Conclusions We found a more persistent association for subsequent asthma and wheeze in children whose first severe RSV infection occurred at 6–23 months compared to those whose first severe RSV infection occurred at 0–6 months. This provides new evidence for further assessment of the association and RSV intervention programs.

Published
2023
Full Text
View/download PDF

30. Defining the Burden of Disease of RSV in the European Union: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study

Author

Del Riccio, Marco, Spreeuwenberg, Peter, Osei-Yeboah, Richard, Johannesen, Caroline K, Vazquez Fernandez, Liliana, Teirlinck, Anne C, Wang, Xin, Heikkinen, Terho, Bangert, Mathieu, Caini, Saverio, Campbell, Harry, and Paget, John

Subjects
Europe, Respiratory Hospitalisation, Burden of disease, Hospitalisation, Respiratory Syncytial Virus, Modelling
Published
2023

31. Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom

Author

Zeevat, F, Luttjeboer, J, Paulissen, J H J, van der Schans, J, Beutels, P, Boersma, C, Postma, M J, Nair, Harish, Campbell, Harry, Openshaw, Peter, Beutels, Philippe, Bont, Louis, Pollard, Andrew, Molero, Eva, Martinon-Torres, Federico, Heikkinen, Terho, Meijer, Adam, Kølsen Fischer, Thea, van den Berge, Maarten, Giaquinto, Carlo, Kieffer, Alexia, Demont, Clarisse, Gallichan, Scott, Dormitzer, Philip, Leach, Amanda, Dillon, Laura, Aerssens, Jeroen, Rosen, Brian, RESCEU Investigators, Value, Affordability and Sustainability (VALUE), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), and Microbes in Health and Disease (MHD)

Subjects
Rsv vaccine, business.industry, Cost effectiveness, Incidence (epidemiology), MEDLINE, The Netherlands, Exploratory analysis, United Kingdom, Vaccination, Infectious Diseases, Elderly, Older adults, Preventive intervention, Immunology and Allergy, Medicine, Cost-effectiveness, Human medicine, Respiratory Syncytial Virus, business, Biology, health care economics and organizations, RSV Vaccines, Demography
Abstract

Background In older adults, the burden of respiratory syncytial virus (RSV) resembles that of influenza and may even be considered worse due to the lack of preventive interventions. This study was performed to identify the available literature on RSV infection in older adults, and to provide updated exploratory results of the cost-effectiveness of a hypothetical RSV vaccine in the Netherlands and the United Kingdom. Methods A literature search was performed in Medline and EMBASE on 11 November 2019, which served as input for a static decision-tree model that was used to estimate the EJP, for an RSV vaccine applying different willingness-to-pay (WTP) thresholds. WTP thresholds applied were €20 000 and €50 000 per quality-adjusted life-year for the Netherlands, and £20 000 and £30 000 per quality-adjusted life-year for the United Kingdom. Analyses were—in line with country-specific guidelines—conducted from a societal perspective for the Netherlands and a third-party payer perspective for the United Kingdom. The robustness of the cost-effectiveness results was tested in sensitivity analysis. Results After screening the literature, 3 studies for the Netherlands and 6 for the United Kingdom remained to populate the country-specific models. In the base case analysis for the Netherlands (mean RSV incidence, 3.32%), justifiable vaccine prices of €16.38 and €50.03 were found, based on applying the lower and higher WTP thresholds, respectively. Similarly, for the United Kingdom (mean incidence, 7.13%), vaccine prices of £72.29 and £109.74 were found, respectively. Conclusion RSV vaccination may well be cost-effective in both the Netherlands and the United Kingdom, depending on the exact RSV incidence, vaccine effectiveness and price. However, sensitivity analysis showed that the results were robust based on varying the different parameter estimates and assumptions. With RSV vaccines reaching the final stages of development, a strong need exists for cost-effectiveness studies to understand economically justifiable pricing of the vaccine.

Published
2022

32. Priority Needs for Conducting Pandemic-Relevant Clinical Research With Children in Europe: A Consensus Study With Pediatric Clinician-Researchers

Author

Gal, Micaela, Gobat, Nina, Francis, Nicholas A., Hood, Kerenza, Butler, Christopher C., Bielicki, Julia, Fraaij, Pieter L., Sharland, Mike, Jarvis, Jessica, van Rossum, Annemarie M.C., Heikkinen, Terho, Martinon-Torres, Federico, Herberg, Jethro, Watkins, Angela, Webb, Steve A.R., Moore, Ronnie, Sukumar, Prasanth, and Nichol, Alistair

Published
2018
Full Text
View/download PDF

33. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data

Author

Infectieziekten onderzoek1 (Bont), Infection & Immunity, MMB Research line 3a, CTI Bont, Child Health, Wilkins, Deidre, Langedijk, Annefleur C., Lebbink, Robert Jan, Morehouse, Christopher, Abram, Michael E., Ahani, Bahar, Aksyuk, Anastasia A., Baraldi, Eugenio, Brady, Tyler, Chen, Albert Tian, Chi, Hsin, Choi, Eun Hwa, Cohen, Robert, Danilenko, Daria M., Gopalakrishnan, Vancheswaran, Greenough, Anne, Heikkinen, Terho, Hosoya, Mitsuaki, Keller, Christian, Kelly, Elizabeth J., Kragten-Tabatabaie, Leyla, Martinón-Torres, Federico, de Los Santos, Abiel Homero Mascareñas, Nunes, Marta C., Palomino, María Angélica, Papenburg, Jesse, Pernica, Jeffrey M., Richmond, Peter, Stein, Renato T., Tuffy, Kevin M., Verwey, Charl, Esser, Mark T., Tabor, David E., Bont, Louis J., Clement, Pascale, Gupta, Atul, Hashimoto, Koichi, Komissarova, Kseniya, Laubscher, Matt, Lumertz, Magali, Priante, Elena, Rivero-Calle, Irene, Wadia, Ushma, Yun, Ki Wook, Infectieziekten onderzoek1 (Bont), Infection & Immunity, MMB Research line 3a, CTI Bont, Child Health, Wilkins, Deidre, Langedijk, Annefleur C., Lebbink, Robert Jan, Morehouse, Christopher, Abram, Michael E., Ahani, Bahar, Aksyuk, Anastasia A., Baraldi, Eugenio, Brady, Tyler, Chen, Albert Tian, Chi, Hsin, Choi, Eun Hwa, Cohen, Robert, Danilenko, Daria M., Gopalakrishnan, Vancheswaran, Greenough, Anne, Heikkinen, Terho, Hosoya, Mitsuaki, Keller, Christian, Kelly, Elizabeth J., Kragten-Tabatabaie, Leyla, Martinón-Torres, Federico, de Los Santos, Abiel Homero Mascareñas, Nunes, Marta C., Palomino, María Angélica, Papenburg, Jesse, Pernica, Jeffrey M., Richmond, Peter, Stein, Renato T., Tuffy, Kevin M., Verwey, Charl, Esser, Mark T., Tabor, David E., Bont, Louis J., Clement, Pascale, Gupta, Atul, Hashimoto, Koichi, Komissarova, Kseniya, Laubscher, Matt, Lumertz, Magali, Priante, Elena, Rivero-Calle, Irene, Wadia, Ushma, and Yun, Ki Wook

Published
2023

34. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape

Author

Infectieziekten onderzoek1 (Bont), Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, CTI Bont, Mazur, Natalie I, Terstappen, Jonne, Baral, Ranju, Bardají, Azucena, Beutels, Philippe, Buchholz, Ursula J, Cohen, Cheryl, Crowe, James E, Cutland, Clare L, Eckert, Linda, Feikin, Daniel, Fitzpatrick, Tiffany, Fong, Youyi, Graham, Barney S, Heikkinen, Terho, Higgins, Deborah, Hirve, Siddhivinayak, Klugman, Keith P, Kragten-Tabatabaie, Leyla, Lemey, Philippe, Libster, Romina, Löwensteyn, Yvette, Mejias, Asuncion, Munoz, Flor M, Munywoki, Patrick K, Mwananyanda, Lawrence, Nair, Harish, Nunes, Marta C, Ramilo, Octavio, Richmond, Peter, Ruckwardt, Tracy J, Sande, Charles, Srikantiah, Padmini, Thacker, Naveen, Waldstein, Kody A, Weinberger, Dan, Wildenbeest, Joanne, Wiseman, Dexter, Zar, Heather J, Zambon, Maria, Bont, Louis, Infectieziekten onderzoek1 (Bont), Infection & Immunity, Infectieziekten onderzoek2 (Wildenbeest), Infectieziekten patientenzorg, Child Health, CTI Bont, Mazur, Natalie I, Terstappen, Jonne, Baral, Ranju, Bardají, Azucena, Beutels, Philippe, Buchholz, Ursula J, Cohen, Cheryl, Crowe, James E, Cutland, Clare L, Eckert, Linda, Feikin, Daniel, Fitzpatrick, Tiffany, Fong, Youyi, Graham, Barney S, Heikkinen, Terho, Higgins, Deborah, Hirve, Siddhivinayak, Klugman, Keith P, Kragten-Tabatabaie, Leyla, Lemey, Philippe, Libster, Romina, Löwensteyn, Yvette, Mejias, Asuncion, Munoz, Flor M, Munywoki, Patrick K, Mwananyanda, Lawrence, Nair, Harish, Nunes, Marta C, Ramilo, Octavio, Richmond, Peter, Ruckwardt, Tracy J, Sande, Charles, Srikantiah, Padmini, Thacker, Naveen, Waldstein, Kody A, Weinberger, Dan, Wildenbeest, Joanne, Wiseman, Dexter, Zar, Heather J, Zambon, Maria, and Bont, Louis

Published
2023

35. Burden of Respiratory Syncytial Virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years.

Author

Riccio, Marco Del, Spreeuwenberg, Peter, Osei-Yeboah, Richard, Johannesen, Caroline K, Fernandez, Liliana Vazquez, Teirlinck, Anne C, Wang, Xin, Heikkinen, Terho, Bangert, Mathieu, Caini, Saverio, Campbell, Harry, Paget, John, and Investigators, the RESCEU

Subjects
RESPIRATORY syncytial virus, HOSPITAL care, AGE groups
Abstract

Background No overall estimate of respiratory syncytial virus (RSV)-associated hospitalizations in children aged under 5 years has been published for the European Union (EU). We aimed to estimate the RSV hospitalization burden in children aged under 5 years in EU countries and Norway, by age group. Methods We collated national RSV-associated hospitalization estimates calculated using linear regression models via the RESCEU project for Denmark, England, Finland, Norway, the Netherlands, and Scotland, 2006–2018. Additional estimates were obtained from a systematic review. Using multiple imputation and nearest neighbor matching methods, we estimated overall RSV-associated hospitalizations and rates in the EU. Results Additional estimates for 2 countries (France and Spain) were found in the literature. In the EU, an average of 245 244 (95% confidence interval [CI], 224 688–265 799) yearly hospital admissions with a respiratory infection per year were associated with RSV in children aged under 5 years, with most cases occurring among children aged under 1 year (75%). Infants aged under 2 months represented the most affected group (71.6 per 1000 children; 95% CI, 66.6–76.6). Conclusions Our findings will help support decisions regarding prevention efforts and represent an important benchmark to understand changes in the RSV burden following the introduction of RSV immunization programs in Europe. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Prioritising respiratory syncytial virus prevention in low-income and middle-income countries

Author

Carbonell-Estrany, Xavier, primary, Simões, Eric AF, additional, Bont, Louis J, additional, Paes, Bosco A, additional, Carbonell-Estrany, Xavier, additional, Ayuk, Adaeze, additional, Gentile, Angela, additional, Greenough, Anne, additional, Moreno, Antonio, additional, Sharma, Arun, additional, Mejias, Asuncion, additional, Rodgers-Gray, Barry, additional, Resch, Bernhard, additional, Fauroux, Brigette, additional, Rodriguez-Martinez, Carlos E, additional, El Saleeby, Chadi, additional, Huskins, W Charles, additional, Cohen, Cheryl, additional, Greenberg, David, additional, Baraldi, Eugenio, additional, Anderson, Evan, additional, Martinon Torres, Federico, additional, Polack, Fernando F, additional, Piedimonte, Giovanni, additional, Nair, Harish, additional, Gans, Hayley, additional, Zar, Heather J, additional, Moriuchi, Hiroyuki, additional, Oshitani, Hitoshi, additional, Mitchell, Ian, additional, Nokes, D James, additional, Sheikh, Jarju, additional, Pernica, Jeffrey, additional, Papenburg, Jesse, additional, Robinson, Joan, additional, De Jesus-Cornejo, Joanne, additional, Langley, Joanne, additional, Liese, Johannes, additional, Figueras Aloy, Jose, additional, Torres Torretti, Juan Pablo, additional, Edwards, Kathryn, additional, Krilov, Leonard, additional, Divaratne, Maduja, additional, Sanchez Luna, Manuel, additional, Lanari, Marcello, additional, Scotta, Marcelo, additional, Garba, Maria, additional, Mori, Masaaki, additional, Cetinkaya, Merih, additional, Goldstein, Mitchell, additional, Khuri-Bulos, Najwa, additional, Vain, Nestor E, additional, Papadopoulus, Nikolaos, additional, Homaira, Nusrat, additional, Ramilo, Octavio, additional, Manzoni, Paolo, additional, Munywoki, Patrick, additional, Piedra, Pedro A, additional, Moschovis, Peter, additional, Openshaw, Peter, additional, Bassat, Quique, additional, Stein, Renato, additional, Thwaites, Richard, additional, Muthugala, Rohitha, additional, Ulloa-Gutierrez, Rolando, additional, Dagan, Ron, additional, Rodriguez Fernandez, Rosa, additional, Kusuda, Satoshi, additional, Madhi, Shabir, additional, Broor, Shobha, additional, Drysdale, Simon B, additional, Basnet, Sudha, additional, Heikkinen, Terho, additional, Avadhanula, Vasanthi, additional, Saez-Llorens, Xavier, additional, Wang, Xin, additional, Li, You, additional, and Mathew, Joseph L, additional

Published
2023
Full Text
View/download PDF

37. Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe

Author

Mao, Zhuxin, primary, Li, Xiao, additional, Dacosta-Urbieta, Ana, additional, Billard, Marie-Noëlle, additional, Wildenbeest, Joanne, additional, Korsten, Koos, additional, Martinón-Torres, Federico, additional, Heikkinen, Terho, additional, Cunningham, Steve, additional, Snape, Matthew D., additional, Robinson, Hannah, additional, Pollard, Andrew J., additional, Postma, Maarten, additional, Dervaux, Benoit, additional, Hens, Niel, additional, Bont, Louis, additional, Bilcke, Joke, additional, and Beutels, Philippe, additional

Published
2023
Full Text
View/download PDF

38. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data

Author

Wilkins, Deidre, primary, Langedijk, Annefleur C, additional, Lebbink, Robert Jan, additional, Morehouse, Christopher, additional, Abram, Michael E, additional, Ahani, Bahar, additional, Aksyuk, Anastasia A, additional, Baraldi, Eugenio, additional, Brady, Tyler, additional, Chen, Albert Tian, additional, Chi, Hsin, additional, Choi, Eun Hwa, additional, Cohen, Robert, additional, Danilenko, Daria M, additional, Gopalakrishnan, Vancheswaran, additional, Greenough, Anne, additional, Heikkinen, Terho, additional, Hosoya, Mitsuaki, additional, Keller, Christian, additional, Kelly, Elizabeth J, additional, Kragten-Tabatabaie, Leyla, additional, Martinón-Torres, Federico, additional, de Los Santos, Abiel Homero Mascareñas, additional, Nunes, Marta C, additional, Palomino, María Angélica, additional, Papenburg, Jesse, additional, Pernica, Jeffrey M, additional, Richmond, Peter, additional, Stein, Renato T, additional, Tuffy, Kevin M, additional, Verwey, Charl, additional, Esser, Mark T, additional, Tabor, David E, additional, Bont, Louis J, additional, Clement, Pascale, additional, Gupta, Atul, additional, Hashimoto, Koichi, additional, Komissarova, Kseniya, additional, Laubscher, Matt, additional, Lumertz, Magali, additional, Priante, Elena, additional, Rivero-Calle, Irene, additional, Wadia, Ushma, additional, and Yun, Ki Wook, additional

Published
2023
Full Text
View/download PDF

40. Economic Burden and Health-Related Quality of Life of Respiratory Syncytial Virus and Influenza Infection in European Community-Dwelling Older Adults

Author

Mao, Zhuxin, Li, Xiao, Korsten, Koos, Bont, Louis, Butler, Christopher, Wildenbeest, Joanne, Coenen, Samuel, Hens, Niel, Bilcke, Joke, Beutels, Philippe, Nair, Harish, Campbell, Harry, Pollard, Andrew, Openshaw, Peter, Martinon-Torres, Federico, Heikkinen, Terho, Meijer, Adam, Fischer, Thea K, van den Berge, Maarten, Giaquinto, Carlo, Abram, Michael, Swanson, Kena, Rizkalla, Bishoy, Vernhes, Charlotte, Gallichan, Scott, Aerssens, Jeroen, Kumar, Veena, Molero, Eva, Coenen, Samuel/0000-0002-1238-8052, Mao, Zhuxin, Li, Xiao, Korsten, Koos, BONTE, Luis, Butler, Christopher, Wildenbeest, Joanne, COENEN, Samuel, HENS, Niel, Bilcke, Joke, Beutels, Philippe, and RESCEU Investigators

Subjects
Financial Stress, Respiratory Syncytial Virus Infections, elderly, cost, EQ5D, Influenza, Human, Humans, Immunology and Allergy, Biology, Aged, flu, RSV, Middle Aged, outpatients, health-related quality of life, Hospitalization, productivity loss, Infectious Diseases, Respiratory Syncytial Virus, Human, influenza, prospective study, Independent Living, Quality of Life, Human medicine, Respiratory Syncytial Virus, costproductivity loss, Human
Abstract

Background Respiratory syncytial virus (RSV) and influenza virus infections result in a considerable mortality and morbidity among the aging population globally. Influenza vaccination for older adults before the seasonal influenza epidemic has been evaluated to be cost-effective in many countries. Interventions against RSV in older adults are in the pipeline, and evaluating their cost-effectiveness is crucial for decision making. To inform such evaluations, our aim was to estimate average costs and health-related quality of life (HRQoL) in older adults with RSV and influenza infection. Methods The European RESCEU observational cohort study followed 1040 relatively healthy community-dwelling older adults aged 60 years and older during 2 consecutive winter seasons. Health care resource use and HRQoL were collected and analyzed during RSV episodes, and also during influenza episodes. Country-specific unit cost data were mainly obtained from national databases. Direct costs were estimated from a patient, health care provider, and health care payers’ perspective, whereas indirect costs were estimated from a societal perspective. Due to small sample size, no formal statistical comparisons were made. Results Thirty-six RSV and 60 influenza episodes were reported, including 1 hospitalization. Means (median; first-third quartile) of €26.4 (€5.5; 0–47.3) direct and €4.4 (€0; 0–0) indirect costs were reported per nonhospitalized RSV episode, and €42.5 (€36; 3.3–66.7) direct and €32.1 (€0; 0–0) indirect costs per nonhospitalized influenza episode. For RSV episodes, the utility value decreased from 0.896 (0.928; 0.854–0.953) to 0.801 (0.854; 0.712–0.937) from preseason to 1 week after symptom onset; for influenza, the change was from 0.872 (0.895; 0.828–0.953) to 0.664 (0.686; 0.574–0.797). Conclusions The average costs and HRQoL estimates of older adults treated outside the hospital can be used to inform the design of future studies and the decision making regarding interventions to prevent RSV infection in older adults. Larger studies are needed to provide better country-specific and complementary cost estimates and to allow for formal statistical comparison of costs between RSV and influenza. Clinical Trials Registration NCT03621930.

Published
2022
Full Text
View/download PDF

41. Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children

Author

Li, Xiao, Bilcke, Joke, Vázquez Fernández, Liliana, Bont, Louis, Willem, Lander, Wisløff, Torbjørn, Jit, Mark, Beutels, Philippe, Nair, Harish, Campbell, Harry, Pollard, Andrew, Openshaw, Peter, Martinon-Torres, Federico, Heikkinen, Terho, Meijer, Adam, Fischer, Thea K, van den Berge, Maarten, Giaquinto, Carlo, Abram, Michael, Swanson, Kena, Rizkalla, Bishoy, Vernhes, Charlotte, Gallichan, Scott, Aerssens, Jeroen, Kumar, Veena, Molero, Eva, and REsp Syncytial Virus Consortium EU (RESCEU)

Subjects
Vaccines, Cost-Benefit Analysis, Infant, Newborn, Antibodies, Monoclonal, Infant, Respiratory Syncytial Virus Infections, Antibodies, Monoclonal, Humanized, Antiviral Agents, Communicable Diseases, Respiratory Syncytial Viruses, Infectious Diseases, Child, Preschool, Humans, Immunology and Allergy, Seasons, Human medicine, Child, Biology, Palivizumab
Abstract

Background Every winter, respiratory syncytial virus (RSV) disease results in thousands of cases in Norwegian children under 5 years of age. We aim to assess the RSV-related economic burden and the cost-effectiveness of upcoming RSV disease prevention strategies including year-round maternal immunization and year-round and seasonal monoclonal antibody (mAb) programs. Methods Epidemiological and cost data were obtained from Norwegian national registries, while quality-adjusted life-years (QALYs) lost and intervention characteristics were extracted from literature and phase 3 clinical trials. A static model was used and uncertainty was accounted for probabilistically. Value of information was used to assess decision uncertainty. Extensive scenario analyses were conducted, including accounting for long-term consequences of RSV disease. Results We estimate an annual average of 13 517 RSV cases and 1572 hospitalizations in children under 5, resulting in 79.6 million Norwegian kroner (~€8 million) treatment costs. At €51 per dose for all programs, a 4-month mAb program for neonates born in November to February is the cost-effective strategy for willingness to pay (WTP) values up to €40 000 per QALY gained. For higher WTP values, the longer 6-month mAb program that immunizes neonates from October to March becomes cost-effective. Sensitivity analyses show that year-round maternal immunization can become a cost-effective strategy if priced lower than mAb. Conclusions Assuming the same pricing, seasonal mAb programs are cost-effective over year-round programs in Norway. The timing and duration of the cost-effective seasonal program are sensitive to the pattern of the RSV season in a country, so continued RSV surveillance data are essential.

Published
2022
Full Text
View/download PDF

42. Burden of Respiratory Syncytial Virus in the European Union:estimation of RSV-associated hospitalizations in children under 5 years

Author

Del Riccio, Marco, Spreeuwenberg, Peter, Osei-Yeboah, Richard, Johannesen, Caroline K, Vazquez Fernandez, Liliana, Teirlinck, Anne C, Wang, Xin, Heikkinen, Terho, Bangert, Mathieu, Caini, Saverio, Campbell, Harry, and Paget, John

Subjects
Europe, modelling, respiratory syncytial virus, respiratory hospitalization, burden of disease, hospitalization
Abstract

Background: To date, no overall estimate of RSV-associated hospitalisations in children under 5 years has been published for the European Union (EU). We aimed to estimate the RSV hospitalisation burden in children under 5 years in EU countries and Norway, by age group and country.Methods: We collated national RSV-associated hospitalisation estimates calculated using linear regression models via the RESCEU project for Denmark, England, Finland, Norway, the Netherlands and Scotland during 2006-2018. A systematic review was conducted to collect additional estimates. Using the multiple imputation and nearest neighbour matching methods, we estimated overall RSV-associated hospitalisations and rates in the EU. Results: Additional estimates for only two countries (France and Spain) were found in the literature. In the EU, an average of 245,244 (95%CI 224,688-265,799) hospital admissions with a respiratory infection per year were associated with RSV in children under the age of 5, with most cases occurring among children aged less than 1 year (75%). Infants aged less than 2 months represented the most affected group (71.6 per 1,000 children; 66.6-76.6). The hospitalisation rates varied widely across countries: in children aged 0-2 months, they ranged from 47.4 (37.5-57.3) per 1,000 in the Netherlands to 98.3 (88.5-108.1) per 1,000 in France. Conclusion: This is the first attempt to estimate the overall RSV hospitalisation burden in children under the age of 5 years in the EU. Our findings will help support decisions regarding prevention efforts and represent an important benchmark to understand changes in the RSV burden following the introduction of RSV immunisation programs in Europe.

Published
2023
Full Text
View/download PDF

43. Defining the Burden of Disease of RSV in Europe: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study

Author

Del Riccio, Marco, primary, Spreeuwenberg, Peter, additional, Osei-Yeboah, Richard, additional, Johannesen, Caroline K., additional, Fernandez, Liliana Vazquez, additional, Teirlinck, Anne C., additional, Wang, Xin, additional, Heikkinen, Terho, additional, Bangert, Mathieu, additional, Caini, Saverio, additional, Campbell, Harry, additional, and Paget, John, additional

Published
2023
Full Text
View/download PDF

44. Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries

Author

Getaneh, Abraham M., primary, Li, Xiao, additional, Mao, Zhuxin, additional, Johannesen, Caroline K., additional, Barbieri, Elisa, additional, van Summeren, Jojanneke, additional, Wang, Xin, additional, Tong, Sabine, additional, Baraldi, Eugenio, additional, Phijffer, Emily, additional, Rizzo, Caterina, additional, van Wijhe, Maarten, additional, Heikkinen, Terho, additional, Bont, Louis, additional, Willem, Lander, additional, Jit, Mark, additional, Beutels, Philippe, additional, and Bilcke, Joke, additional

Published
2023
Full Text
View/download PDF

47. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study

Author

Wildenbeest, Joanne G, primary, Billard, Marie-Noëlle, additional, Zuurbier, Roy P, additional, Korsten, Koos, additional, Langedijk, Annefleur C, additional, van de Ven, Peter M, additional, Snape, Matthew D, additional, Drysdale, Simon B, additional, Pollard, Andrew J, additional, Robinson, Hannah, additional, Heikkinen, Terho, additional, Cunningham, Steve, additional, O'Neill, Thomas, additional, Rizkalla, Bishoy, additional, Dacosta-Urbieta, Ana, additional, Martinón-Torres, Federico, additional, van Houten, Marlies A, additional, Bont, Louis J, additional, Wildenbeest, Joanne, additional, Zuurbier, Roy, additional, van Houten, Marlies, additional, Langedijk, Annefleur, additional, van de Ven, Peter, additional, Bont, Louis, additional, Drysdale, Simon, additional, McGinley, Joseph, additional, Lin, Gu-Lung, additional, Snape, Matthew, additional, Pollard, Andrew, additional, Ives, Andrew, additional, Wolfenden, Helen, additional, Salgia, Sanjay, additional, Shetty, Rohoth, additional, Rivero-Calle, Irene, additional, Gómez-Carballa, Alberto, additional, Pischedda, Sara, additional, Rodriguez-Tenreiro, Carmen, additional, Nair, Harish, additional, Campbell, Harry, additional, Miller, Margaret, additional, Baggott, Julie, additional, Beveridge, Catherine, additional, McKernan, Rachael, additional, Beutels, Philippe, additional, Openshaw, Peter, additional, Meijer, Adam, additional, Kølsen Fischer, Thea, additional, van den Berge, Maarten, additional, Giaquinto, Carlo, additional, Abram, Michael, additional, Swanson, Kena, additional, Aerssens, Jeroen, additional, Vernhes, Charlotte, additional, Gallichan, Scott, additional, Kumar, Veena, additional, and Molero, Eva, additional

Published
2022
Full Text
View/download PDF

49. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study

Author

Wildenbeest, Joanne G, Billard, Marie-Noëlle, Zuurbier, Roy P, Korsten, Koos, Langedijk, Annefleur C, van de Ven, Peter M, Snape, Matthew D, Drysdale, Simon B, Pollard, Andrew J, Robinson, Hannah, Heikkinen, Terho, Cunningham, Steve, O'Neill, Thomas, Rizkalla, Bishoy, Dacosta-Urbieta, Ana, Martinón-Torres, Federico, van Houten, Marlies A, Bont, Louis J, Wildenbeest, Joanne, Billard, Marie-Noëlle, Zuurbier, Roy, Korsten, Koos, van Houten, Marlies, Langedijk, Annefleur, van de Ven, Peter, Bont, Louis, Drysdale, Simon, McGinley, Joseph, Lin, Gu-Lung, Snape, Matthew, Pollard, Andrew, Ives, Andrew, Wolfenden, Helen, Salgia, Sanjay, Shetty, Rohoth, Dacosta-Urbieta, Ana, Rivero-Calle, Irene, Gómez-Carballa, Alberto, Pischedda, Sara, Rodriguez-Tenreiro, Carmen, Martinón-Torres, Federico, Heikkinen, Terho, Cunningham, Steve, Nair, Harish, Campbell, Harry, O'Neill, Thomas, Miller, Margaret, Baggott, Julie, Beveridge, Catherine, McKernan, Rachael, Rizkalla, Bishoy, Beutels, Philippe, Openshaw, Peter, Meijer, Adam, Kølsen Fischer, Thea, van den Berge, Maarten, Giaquinto, Carlo, Abram, Michael, Swanson, Kena, Aerssens, Jeroen, Vernhes, Charlotte, Gallichan, Scott, Kumar, Veena, and Molero, Eva

Abstract

Respiratory syncytial virus (RSV) is a major cause of hospitalisation in infants. The burden of RSV infection in healthy term infants has not yet been established. Accurate health-care burden data in healthy infants are necessary to determine RSV immunisation policy when RSV immunisation becomes available.

Published
2023
Full Text
View/download PDF

50. Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis

Author

Johannesen, Caroline K, van Wijhe, Maarten, Tong, Sabine, Fernández, Liliana V, Heikkinen, Terho, van Boven, Michiel, Wang, Xin, Bøås, Håkon, Li, You, Campbell, Harry, Paget, John, Stona, Luca, Teirlinck, Anne, Lehtonen, Toni, Nohynek, Hanna, Bangert, Mathieu, and Fischer, Thea K

Subjects
respiratory syncytial virus, time series analysis, public health, RSV, burden of disease, viral hospitalizations
Published
2022

Catalog

Books, media, physical & digital resources
See catalog results